We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Assay System Detects and Quantifies Exogenous Pyrogens

By LabMedica International staff writers
Posted on 18 May 2010
A pyrogen assay system detects endotoxins, pyrogenic substances from gram-positive bacteria (lipoteichoic acid), as well as pyrogenic particles from molds and yeasts, viruses, and environmental contaminants, such as packaging material.

The test involves two main steps: incubation of the sample in human whole blood and the IL-1ß enzyme-linked immunosorbent assay (ELISA). More...
The sample is mixed with the pooled, freeze-stored cryoblood or fresh blood and incubated. During the incubation, the blood's monocytes produce IL-1ß if the sample contains any pyrogens.

The mixture is transferred to a microplate coated with an antibody that specifically binds IL-1ß. The subsequent ELISA allows the concentration of the bound IL-1ß to be determined. The pyrogen concentration can then be determined using a standard curve.

The assay covers the same full range of pyrogens as the rabbit test and a much broader spectrum than the limulus amebocyte lysate (LAL) test, which detects only endotoxins--lipopolysaccharides--in the outer membrane of gram-negative bacteria.

An addition to Biotest's (Dreieich, Germany) portfolio for laboratories, the PyroDetect system uses human whole blood and therefore can replace all animal pyrogen tests available on the market. It supports a uniquely broad range of applications in medical devices, biologics, pharmaceutics, and cell therapeutics.

Dr. Frank Schulze, executive vice president of microbiology at Biotest AG commented, "There are many products that the existing pyrogen tests cannot reliably test. For example, the rabbit test is unsuitable for cytostatic drugs, sedatives, cytokines, antibiotics, chemotherapeutics, and proteins, the LAL test for blood, lipids, cell therapeutics, and solids. PyroDetect puts an end to these constraints while, at the same time, advancing animal welfare.”

Related Links:

Biotest AG




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.